<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00168298</url>
  </required_header>
  <id_info>
    <org_study_id>206207-009</org_study_id>
    <nct_id>NCT00168298</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone
      for the treatment of macular edema associated with retinal vein occlusion.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With 15 or More Letter Improvement in Best Corrected Visual Acuity (BCVA) in the Study Eye</measure>
    <time_frame>Day 180</time_frame>
    <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. The numbers of patients with at least a 15 or more letter improvement in BCVA in the study eye are presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Retinal Thickness in the Study Eye</measure>
    <time_frame>Baseline, Day 90, Day 180</time_frame>
    <description>Retinal thickness is assessed by optical coherence tomography (OCT) in the study eye. The retina is the light-sensitive part of the eye. OCT is a laser-based, noninvasive, diagnostic system providing high-resolution, three-dimensional images of the retina. A negative change from baseline indicates an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With a Change From Baseline in BCVA by Category</measure>
    <time_frame>Baseline, Day 90</time_frame>
    <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Data are grouped into the following 5 categories based on change from baseline: ≥15 Letters Improvement, ≥5 and &lt;15 Letters Improvement, No Change (Between -5 to +5 Letters), ≥5 and &lt;15 Letters Worsening, and ≥15 Letters Worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With a Change From Baseline in BCVA by Category</measure>
    <time_frame>Baseline, Day 180</time_frame>
    <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Data are grouped into the following 5 categories based on change from baseline: ≥15 Letters Improvement, ≥5 and &lt;15 Letters Improvement, No Change (Between -5 to +5 Letters), ≥5 and &lt;15 Letters Worsening, and ≥15 Letters Worsening.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">668</enrollment>
  <condition>Macular Edema</condition>
  <condition>Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>700 µg Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>700 µg dexamethasone intravitreal implant administered on Day 0 and Day 180.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>350 µg Dexamethasone followed by 700 µg Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>350 µg dexamethasone intravitreal implant administered on Day 0 and 700 µg dexamethasone intravitreal implant on Day 180.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Injection followed by 700 µg Dexamethasone</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham injection on Day 0 and 700 µg dexamethasone intravitreal implant on Day 180.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>700 µg Dexamethasone</intervention_name>
    <description>700 µg dexamethasone intravitreal implant administered on Day 0 and/or Day 180.</description>
    <arm_group_label>700 µg Dexamethasone</arm_group_label>
    <arm_group_label>350 µg Dexamethasone followed by 700 µg Dexamethasone</arm_group_label>
    <arm_group_label>Sham Injection followed by 700 µg Dexamethasone</arm_group_label>
    <other_name>Posurdex®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>350 µg Dexamethasone</intervention_name>
    <description>350 µg Dexamethasone intravitreal implant administered on Day 0.</description>
    <arm_group_label>350 µg Dexamethasone followed by 700 µg Dexamethasone</arm_group_label>
    <other_name>Posurdex®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham Injection</intervention_name>
    <description>Sham injection on Day 0.</description>
    <arm_group_label>Sham Injection followed by 700 µg Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  18 years of age or older with macular edema resulting from retinal vein occlusion

          -  Decrease in visual acuity in at least one eye as a result of macular edema (20/50 or
             worse)

          -  Visual acuity in other eye no worse than 20/200

        Key Exclusion Criteria:

          -  Known anticipated need for ocular surgery within next 12 months

          -  History of glaucoma or current high eye pressure requiring more than 1 medication

          -  Diabetic retinopathy

          -  Uncontrolled systemic disease

          -  Known steroid-responder

          -  Use of systemic steroids

          -  Use of warfarin/heparin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kowloon</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tamil Nadu</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Hong Kong</country>
    <country>India</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <results_first_submitted>July 15, 2009</results_first_submitted>
  <results_first_submitted_qc>July 15, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 26, 2009</results_first_posted>
  <last_update_submitted>July 15, 2013</last_update_submitted>
  <last_update_submitted_qc>July 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Patients were randomly assigned during the double-blind period of the study to treatment with 700 µg dexamethasone, 350 µg dexamethasone, or sham injection on Day 0. Patients who qualified to continue in the open-label period of the study received 700 µg dexamethasone on Day 180.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>700 µg Dexamethasone</title>
          <description>700 µg dexamethasone intravitreal implant administered on Day 0 and Day 180.</description>
        </group>
        <group group_id="P2">
          <title>350 µg Dexamethasone Followed by 700 µg Dexamethasone</title>
          <description>350 µg dexamethasone intravitreal implant administered on Day 0 and 700 µg dexamethasone intravitreal implant on Day 180.</description>
        </group>
        <group group_id="P3">
          <title>Sham Injection Followed by 700 µg Dexamethasone</title>
          <description>Sham injection on Day 0 and 700 µg dexamethasone intravitreal implant on Day 180.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-Blind Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="226"/>
                <participants group_id="P2" count="218"/>
                <participants group_id="P3" count="224"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="214"/>
                <participants group_id="P2" count="206"/>
                <participants group_id="P3" count="209"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Open-Label Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="179">Not all patients who completed the double-blind period entered the open-label period.</participants>
                <participants group_id="P2" count="173">Not all patients who completed the double-blind period entered the open-label period.</participants>
                <participants group_id="P3" count="168">Not all patients who completed the double-blind period entered the open-label period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="172"/>
                <participants group_id="P2" count="168"/>
                <participants group_id="P3" count="160"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>700 µg Dexamethasone</title>
          <description>700 µg dexamethasone intravitreal implant administered on Day 0 and Day 180.</description>
        </group>
        <group group_id="B2">
          <title>350 µg Dexamethasone Followed by 700 µg Dexamethasone</title>
          <description>350 µg dexamethasone intravitreal implant administered on Day 0 and 700 µg dexamethasone intravitreal implant on Day 180.</description>
        </group>
        <group group_id="B3">
          <title>Sham Injection Followed by 700 µg Dexamethasone</title>
          <description>Sham injection on Day 0 and 700 µg dexamethasone intravitreal implant on Day 180.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="226"/>
            <count group_id="B2" value="218"/>
            <count group_id="B3" value="224"/>
            <count group_id="B4" value="668"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;45 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45-65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="111"/>
                    <measurement group_id="B4" value="328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="100"/>
                    <measurement group_id="B4" value="298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="101"/>
                    <measurement group_id="B4" value="318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="123"/>
                    <measurement group_id="B4" value="350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With 15 or More Letter Improvement in Best Corrected Visual Acuity (BCVA) in the Study Eye</title>
        <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. The numbers of patients with at least a 15 or more letter improvement in BCVA in the study eye are presented.</description>
        <time_frame>Day 180</time_frame>
        <population>Intent-to-Treat: all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>700 µg Dexamethasone</title>
            <description>700 µg Dexamethasone intravitreal implant administered on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>350 µg Dexamethasone</title>
            <description>350 µg Dexamethasone intravitreal implant administered on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Sham Injection</title>
            <description>Sham injection on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With 15 or More Letter Improvement in Best Corrected Visual Acuity (BCVA) in the Study Eye</title>
          <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. The numbers of patients with at least a 15 or more letter improvement in BCVA in the study eye are presented.</description>
          <population>Intent-to-Treat: all randomized patients</population>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="218"/>
                <count group_id="O3" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Retinal Thickness in the Study Eye</title>
        <description>Retinal thickness is assessed by optical coherence tomography (OCT) in the study eye. The retina is the light-sensitive part of the eye. OCT is a laser-based, noninvasive, diagnostic system providing high-resolution, three-dimensional images of the retina. A negative change from baseline indicates an improvement.</description>
        <time_frame>Baseline, Day 90, Day 180</time_frame>
        <population>Intent-to-Treat: all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>700 µg Dexamethasone</title>
            <description>700 µg Dexamethasone intravitreal implant administered on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>350 µg Dexamethasone</title>
            <description>350 µg Dexamethasone intravitreal implant administered on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Sham Injection</title>
            <description>Sham injection on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Retinal Thickness in the Study Eye</title>
          <description>Retinal thickness is assessed by optical coherence tomography (OCT) in the study eye. The retina is the light-sensitive part of the eye. OCT is a laser-based, noninvasive, diagnostic system providing high-resolution, three-dimensional images of the retina. A negative change from baseline indicates an improvement.</description>
          <population>Intent-to-Treat: all randomized patients</population>
          <units>Microns (µm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="218"/>
                <count group_id="O3" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="573.6" spread="189.08"/>
                    <measurement group_id="O2" value="566.6" spread="219.63"/>
                    <measurement group_id="O3" value="542.5" spread="185.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-215.6" spread="207.62"/>
                    <measurement group_id="O2" value="-205.5" spread="216.25"/>
                    <measurement group_id="O3" value="-91.1" spread="191.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-132.1" spread="207.20"/>
                    <measurement group_id="O2" value="-150.5" spread="220.78"/>
                    <measurement group_id="O3" value="-127.4" spread="197.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With a Change From Baseline in BCVA by Category</title>
        <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Data are grouped into the following 5 categories based on change from baseline: ≥15 Letters Improvement, ≥5 and &lt;15 Letters Improvement, No Change (Between -5 to +5 Letters), ≥5 and &lt;15 Letters Worsening, and ≥15 Letters Worsening.</description>
        <time_frame>Baseline, Day 90</time_frame>
        <population>Intent-to-Treat: all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>700 µg Dexamethasone</title>
            <description>700 µg Dexamethasone intravitreal implant administered on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>350 µg Dexamethasone</title>
            <description>350 µg Dexamethasone intravitreal implant administered on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Sham Injection</title>
            <description>Sham injection on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With a Change From Baseline in BCVA by Category</title>
          <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Data are grouped into the following 5 categories based on change from baseline: ≥15 Letters Improvement, ≥5 and &lt;15 Letters Improvement, No Change (Between -5 to +5 Letters), ≥5 and &lt;15 Letters Worsening, and ≥15 Letters Worsening.</description>
          <population>Intent-to-Treat: all randomized patients</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="218"/>
                <count group_id="O3" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≥15 Letters Improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.2"/>
                    <measurement group_id="O2" value="25.7"/>
                    <measurement group_id="O3" value="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥5 and &lt;15 Letters Improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.1"/>
                    <measurement group_id="O2" value="39.0"/>
                    <measurement group_id="O3" value="37.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Change (Between -5 to +5 Letters)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.7"/>
                    <measurement group_id="O2" value="26.6"/>
                    <measurement group_id="O3" value="29.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥5 and &lt;15 Letters Worsening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                    <measurement group_id="O2" value="6.4"/>
                    <measurement group_id="O3" value="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥15 Letters Worsening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5"/>
                    <measurement group_id="O2" value="2.3"/>
                    <measurement group_id="O3" value="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With a Change From Baseline in BCVA by Category</title>
        <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Data are grouped into the following 5 categories based on change from baseline: ≥15 Letters Improvement, ≥5 and &lt;15 Letters Improvement, No Change (Between -5 to +5 Letters), ≥5 and &lt;15 Letters Worsening, and ≥15 Letters Worsening.</description>
        <time_frame>Baseline, Day 180</time_frame>
        <population>Intent-to-Treat: all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>700 µg Dexamethasone</title>
            <description>700 µg Dexamethasone intravitreal implant administered on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>350 µg Dexamethasone</title>
            <description>350 µg Dexamethasone intravitreal implant administered on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Sham Injection</title>
            <description>Sham injection on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With a Change From Baseline in BCVA by Category</title>
          <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Data are grouped into the following 5 categories based on change from baseline: ≥15 Letters Improvement, ≥5 and &lt;15 Letters Improvement, No Change (Between -5 to +5 Letters), ≥5 and &lt;15 Letters Worsening, and ≥15 Letters Worsening.</description>
          <population>Intent-to-Treat: all randomized patients</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="218"/>
                <count group_id="O3" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≥15 Letters Improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5"/>
                    <measurement group_id="O2" value="21.6"/>
                    <measurement group_id="O3" value="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥5 and &lt;15 Letters Improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.0"/>
                    <measurement group_id="O2" value="33.9"/>
                    <measurement group_id="O3" value="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Change (Between -5 to +5 Letters)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.0"/>
                    <measurement group_id="O2" value="28.9"/>
                    <measurement group_id="O3" value="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥5 and &lt;15 Letters Worsening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0"/>
                    <measurement group_id="O2" value="10.6"/>
                    <measurement group_id="O3" value="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥15 Letters Worsening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="5.0"/>
                    <measurement group_id="O3" value="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AEs) and Serious Adverse Events (SAEs) are reported for the double-blind treatment period through Month 6.</time_frame>
      <desc>The safety population included all randomized patients who received at least one dose of study medication and was used to assess AEs and SAEs.</desc>
      <group_list>
        <group group_id="E1">
          <title>700 µg Dexamethasone</title>
          <description>700 µg Dexamethasone intravitreal implant administered on Day 0.</description>
        </group>
        <group group_id="E2">
          <title>350 µg Dexamethasone</title>
          <description>350 µg Dexamethasone intravitreal implant administered on Day 0.</description>
        </group>
        <group group_id="E3">
          <title>Sham Injection</title>
          <description>Sham injection on Day 0.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Aneurysmal bone cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="168" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="145" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="94" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Maculopathy</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Retinal exudates</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="225"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>Allergan, Inc.</organization>
      <phone>(714)246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

